 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Norm: | 100mg*112capsules/bottle (box) | Indications:: | Leukemia, Lymphoma |
|---|---|---|---|
| Target:: | BCL-2 | Other Names:: | Venetoclax/Venetoclax/Vicorelax |
| Suggestion: | Subject To Doctor's Recommendations | Save: | Seal And Store At No More Than 30°C |
| Highlight: | oral 100mg 0.25g venetoclax tablet BCL-2,oral 100mg 0.25g venetoclax tablet BCL2,BCL2 oral 100mg 0.25g venetoclax tablet |
||
[Name of drug]
Generic Name: Vincristine Tablets
Trade name: VENCLEXTA
English name: Venetoclax Tablets
Hanyu Pinyin: Weinaikela Pian
[Indications]
It is used in combination with azacitidine for the treatment of patients with primary adult acute myeloid leukemia who are not candidates for strong induction chemotherapy due to comorbidities or who are 75 years of age and older.
[Usage and dosage]
Days 1-3 of the first course are dose creep.
Day 1, 100 mg
Day 2, 200 mg
Day 3, 400 mg
400 mg once daily on day 4 and thereafter for 28 days per treatment course
On days 1-7 of each regimen, the product is administered subcutaneously in combination with azacitidine at a dose of 75 mg/m2.
[Adverse Reaction]
The most common adverse reactions (≥30%, any grade) were nausea, diarrhea, constipation, neutropenia, thrombocytopenia, bleeding, peripheral edema, vomiting, fatigue, febrile neutropenia, rash, and anemia.
Serious adverse reactions were reported in 75% of patients. The most common serious adverse reactions (≥5%) were febrile neutropenia, pneumonitis (excluding fungal pneumonitis), sepsis (excluding fungal sepsis), respiratory failure, and multiple organ dysfunction syndrome.
[Storage]
Keep sealed at a temperature not exceeding 30°C.
Contact Person: Xing
Tel: 15235378613
